Business context and reporting period
Johnson & Johnson’s Form 10-K covers fiscal 2009, ended January 3, 2010; it is not a standalone fourth-quarter report. The company operated through more than 250 subsidiaries, with approximately 115,500 employees, across Consumer, Pharmaceutical, and Medical Devices and Diagnostics.
The filing incorporates its detailed financial statements and management’s discussion from the 2009 Annual Report. Those details are not reproduced in the supplied filing text.
Financial performance and position
- Revenue, earnings, margins, cash flow, debt, and liquidity: The supplied text does not provide clear values. Refer to the incorporated annual report for the consolidated statements and MD&A.
- Research and development: Company-sponsored R&D costs were $7.0 billion in 2009, compared with $7.6 billion in 2008 and $7.7 billion in 2007.
- Share repurchases: Since the $10 billion authorization began in 2007, the company had repurchased 140.4 million shares for $8.9 billion. In fiscal Q4 2009, it purchased 15.3 million shares outside that authorization. The filing says repurchases are funded with available cash and debt and management did not expect the program to affect its triple-A credit rating.
- Scale and operations: The company reported 143 manufacturing facilities worldwide, occupying approximately 21.4 million square feet.
Material changes versus prior periods
- RISPERDAL oral sales fell 57.7% in 2009 following loss of patent protection and market exclusivity; the decline was 37.8% in 2008.
- TOPAMAX lost market exclusivity in March 2009, and sales declined 57.9% versus 2008.
- LEVAQUIN, representing 2.5% of 2009 sales, had a significant patent expiration scheduled for December 20, 2010; U.S. exclusivity was extended through June 20, 2011 under a pediatric extension.
- R&D costs decreased to $7.0 billion from $7.6 billion in 2008.
Outlook, risks, contingencies, and unusual items
- No specific financial guidance or quantified outlook is provided in the supplied text.
- Management describes increasing regulatory scrutiny, healthcare pricing and reimbursement pressures, product safety and compliance requirements, and potential recalls, withdrawals, and civil or criminal penalties as business risks. International operations also face political and economic uncertainty.
- The filing incorporates detailed legal proceedings from the annual report. For environmental remediation proceedings, management stated that outcomes could not be predicted but did not expect a material adverse effect on results, cash flows, or financial position.
- Management concluded that disclosure controls and internal control over financial reporting were effective as of January 3, 2010. PwC audited internal control effectiveness.
Important facts for investors to verify
- Consult the incorporated 2009 Annual Report for revenue, net income, margins, cash flows, balance-sheet liquidity, debt, and segment results; the supplied text does not show those values.
- Review the full legal-proceedings and risk disclosures, including the cautionary statement in Exhibit 99.
- Assess revenue exposure to patent expirations and generic competition, particularly for LEVAQUIN and other products.
- Check the annual report’s details on repurchases, dividends, debt, and the company’s credit-rating assumptions.